TEL AVIV, Israel and BETHESDA, Maryland, February 20, 2018 /PRNewswire/ --
Cannabics Pharmaceuticals Inc. (CNBX), a US public biotechnology company dedicated to the development of personalized anti-cancer diagnostics and palliative treatments based on the therapeutic properties of cannabis, announced the appointment of Yasha Borstein as the company's Chief Data Officer.
With extensive experience spanning big data analytics, machine learning, AI and software development alongside an extended track record in enterprise risk management, Yasha Borstein will oversee the design and implementation of a data governance policy for the company.
At the company's R&D base in Israel, Cannabics is conducting scientific research on cannabinoid formulations to deliver innovative diagnostic procedures for screening cancer. Utilizing advanced detection systems and personalized bioinformatics tools, the biotech company is engaged in delivering supportive data upon which cancer patients and doctors can make informed choices about treatments and possible side effects.
"My challenge is to maximize the value of the highly sensitive data generated by Cannabics as well as ensuring the highest standards of regulatory health compliance and data governance," says Yasha Borstein. "The role presents an exciting opportunity to assist in the advancement of a new approach to cancer Theranostics".
"We're delighted to welcome Yasha to the team as we continue to utilize the latest technologies to conduct research, and collect insightful data that deepens our knowledge and expands our IP portfolio," says Cannabics newly appointed CEO Eyal Barad. "We believe we have engaged the very best and brightest scientists to explore the use of bioinformatic tools to support personalized cannabinoid-based treatments and help combat one of the leading causes of death in our time."
Cannabics will be moving their entire R&D operation into a custom-designed, state of the art Theranostics laboratory in Rehovot, Israel. Their VP of R&D Dr. Moran Grinberg is overseeing the development of this facility, set to open in the coming months.
Yasha Borstein's appointment complements Cannabics' executive leadership team alongside a distinguished advisory board including Dr. Gil Feiler as Business Development Advisor, Dr. Tal Mofkadi as Financial Advisor, Dr. Ariely-Portnoy - Advisor on Pharmaceutical Regulation, Validation & Quality and Amos Toren M.D Ph.D. as Medical Advisor.
About Cannabics Pharmaceuticals Inc.
Cannabics Pharmaceuticals (CNBX), a U.S public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical studies. The Company's scientific focus is on identifying and harnessing the therapeutic properties of specific natural Cannabinoids and is creating individually tailored therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest Form 10-Q Report filed on January 16th, 2018. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc. which are condoned by the Company must emanate from the Company itself, and bear our name as its Source.
For further information, please contact:
SOURCE Cannabics Pharmaceuticals Inc.